Increased Matrix Metalloproteinase-9 to Tissue Inhibitor of Metalloproteinase-1 Ratio in Smokers with Airway Hyperresponsiveness and Accelerated Lung Function Decline
Overview
Authors
Affiliations
Background: Airway hyperresponsiveness (AHR) is associated with airway inflammation and a rapid decline in lung function and is a predictor of future risk of COPD among smokers. Alveolar macrophages (AMs) from patients with COPD release a greater amount of matrix metalloproteinase (MMP)-9. We hypothesized that the imbalance between MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) is related to AHR in smokers.
Patients And Methods: Healthy smokers with AHR (AHR + S) or smokers without AHR (AHR - S; divided according to a methacholine challenge test) and nonsmokers without AHR (AHR - NS) were enrolled. Spirometry was performed during enrollment and repeated after 5 years. Initially, AMs recovered from bronchoalveolar lavage (BAL) fluid were cultured in the presence of p38 mitogen-activated protein kinase (MAPK) inhibitor (SB203580), MAPK kinase (MEK) 1/2 (the MEK of extracellular signal-regulated kinase [ERK] inhibitor, PD98059), or medium alone for 24 h. The release of MMP-9 and TIMP-1 in culture supernatants was measured by enzyme-linked immunosorbent assay.
Results: A greater reduction in forced expiratory volume in 1 s (FEV)/forced vital capacity (FVC), FEV (as a percentage of the predicted value [%pred]), and maximal mid-expiratory flow (MMEF) was observed among AHR + S in the 5-year period. There was a higher proportion of neutrophils and a lower proportion of AMs in BAL fluid recovered from AHR + S. Compared to AMs from AHR - NS and AHR - S, AMs from nonsmokers with AHR (AHR + NS) released more MMP-9 and less TIMP-1, with an increase in MMP-9/TIMP-1 ratios. The MMP-9/TIMP-1 ratio in smokers was positively correlated with the annual decline in FEV%pred, FVC%pred, and MMEF%pred. Both SB203580 and PD98059 significantly reduced MMP-9, but not TIMP-1, from AMs of smokers.
Conclusion: AMs of AHR + NS produce excessive MMP-9 over TIMP-1, which may be a predictor of the development of airway obstruction. Inhibition of p38 MAPK and ERK suppresses the generation of MMP-9 by AMs from smokers.
Lin H, Hsieh M, Lo Y, Huang H, Huang S, Huang C J Inflamm Res. 2024; 17:5701-5709.
PMID: 39219819 PMC: 11366244. DOI: 10.2147/JIR.S465413.
TIMP-1 and its potential diagnostic and prognostic value in pulmonary diseases.
Almuntashiri S, Alhumaid A, Zhu Y, Han Y, Dutta S, Khilji O Chin Med J Pulm Crit Care Med. 2024; 1(2):67-76.
PMID: 38343891 PMC: 10857872. DOI: 10.1016/j.pccm.2023.05.002.
p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics.
Ahmadi A, Ahrari S, Salimian J, Salehi Z, Karimi M, Emamvirdizadeh A Cell Commun Signal. 2023; 21(1):314.
PMID: 37919729 PMC: 10623820. DOI: 10.1186/s12964-023-01337-4.
Zingaropoli M, Latronico T, Pasculli P, Masci G, Merz R, Ciccone F Biomolecules. 2023; 13(7).
PMID: 37509076 PMC: 10377146. DOI: 10.3390/biom13071040.
A2M Serves as Promising Biomarker for Chronic Obstructive Pulmonary Disease.
Xiao X, Cai W, Ding Z, Shi Y, Fan L, Zhang Q Int J Chron Obstruct Pulmon Dis. 2023; 18:683-692.
PMID: 37123074 PMC: 10145514. DOI: 10.2147/COPD.S407491.